Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist administered subcutaneously once weekly, produces significantly greater weight loss than both placebo and semaglutide in patients with type 2 diabetes and obesity.
If you have obesity or Type 2 Diabetes, tirzepatide is a highly effective weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. It causes more weight loss than existing options like semaglutide. While it can cause stomach issues like nausea, these are usually mild and can be managed by starting with a low dose and increasing it slowly over time under medical supervision.
Studies have shown that tirzepatide is more effective in weight loss than placebo and semaglutide, and reduces cardiovascular and metabolic risks.
Why this rating
Based on multiple large-scale, randomized, double-blind, multicenter clinical trials (SURPASS-1, SURPASS-2, SURMOUNT-1).
Source
Thirzepatide. A novelty in the treatment of obesity - literature review
K Wiśniewska et al. · Quality in Sport · 2024
DOI 10.12775/qs.2024.15.52005
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →